Mohsin Sheraz Mughal

Mohsin Sheraz Mughal

Auto-generated profile, based on publicly available information

Mohsin Sheraz Mughal

Internal Medicine, Monmouth Medical Center, Long Branch, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2020 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
MMMohsin Sheraz Mughal
Mohsin Sheraz Mughal
IKIkwinder Preet Kaur
Ikwinder Preet Kaur
CPChandler D. Patton
Chandler D. Patton
NMNagy H. Mikhail
Nagy H. Mikhail
CVChairut Vareechon
Chairut Vareechon
KGKenneth M. Granet
Kenneth M. Granet

11 July 2022 in Cureus
Verified
Journal Article
Open access
HMHasan Mirza
Hasan Mirza
MNMuhammad Atif Masood Noori
Muhammad Atif Masood Noori
HAHafsa Akbar
Hafsa Akbar
HFHardik Fichadiya
Hardik Fichadiya
IKIkwinder Preet Kaur
Ikwinder Preet Kaur
MMMohsin S. Mughal
Mohsin S. Mughal
Despite the lack of direct evidence that hypertension increases the likelihood of new infections, hypertension is known to be the most common comorbid condition in COVID-19 patients and also a major risk factor for severe COVID-19 infection. The literature review suggests that data is heterogeneous in terms of the association of hypertension with mortality. Hence, it remains a topic of interest whether hypertension is associated with COVID-19 disease severity and mortality. Herein, we perform a multicenter retrospective analysis to study hypertension as an independent risk for in-hospital mortality in hospitalized COVID-19 patients. This multicenter retrospective analysis included 515 COVID-19 patients hospitalized from March 1, 2020 to May 31, 2020. Patients were divided into two groups: hypertensive and normotensive. Demographic characteristics and laboratory data were collected, and in-hospital mortality was calculated in both groups. The overall mortality of the study population was 25.3% (130 of 514 patients) with 96 (73.8%) being hypertensive and 34 (26.2%) being normotensive (p-value of 0.01, statistically non-significant association). The mortality rate among the hypertensive was higher as compared to non-hypertensive; however, hypertensive patients were more likely to be old and have underlying comorbidities including obesity, diabetes mellitus, coronary artery disease, congestive heart failure, stroke, chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and cancer. Therefore, multivariable logistic regression failed to show any significant association between hypertension and COVID-19 mortality. To our knowledge, few studies have shown an association between hypertension and COVID-19 mortality after adjusting confounding variables. Our study provides further evidence that hypertension is not an independent risk factor for in-hospital mortality when adjusted for other comorbidities in hospitalized COVID-19 patients.

4 March 2021 in Journal of Community Hospital Internal Medicine Perspectives
Verified
Journal Article
Open access
MMMohsin Sheraz Mughal
Mohsin Sheraz Mughal
IKIkwinder Preet Kaur
Ikwinder Preet Kaur
RAReem Alhashemi
Reem Alhashemi
RRRameez Rehman
Rameez Rehman
DDDoantrang Du
Doantrang Du
Dear Editor,Muscle injury is common in acute viral infections with influenza viruses and enteroviruses being the most commonly reported viruses. It can cause a wide spectrum of symptoms ranging fro...

8 March 2021 in Cureus
Verified
Journal Article
Open access
IKIkwinder Kaur
Ikwinder Kaur
CVCharmee Vyas
Charmee Vyas
MMMohsin Mughal
Mohsin Mughal
HGHaresh Gandhi
Haresh Gandhi
DDDoantrang Du
Doantrang Du
Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has been associated with a significantly increased risk of venous and arterial thromboembolism, particularly in severely sick patients. Recently, cerebral venous sinus thrombosis (CVST) cases have been reported in the context of coronavirus disease-2019 (COVID-19). These cases either had an active COVID infection with a positive reverse transcription-polymerase chain reaction (RT-PCR) or were symptomatic (fever, respiratory symptoms, myalgia) during the presentation. We present here a 41-year-old male with CVST who had negative RT-PCR and positive immunoglobulin G (IgG) COVID-19 antibodies. He was neither diagnosed nor had a flu-like illness before admission. This case highlights that CVST can be a late sequela of previously undiagnosed asymptomatic COVID-19 infection.

9 August 2020 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
MMMohsin Sheraz Mughal
Mohsin Sheraz Mughal
RRRameez Rehman
Rameez Rehman
RORamy Osman
Ramy Osman
NKNathan Kan
Nathan Kan
HMHasan Mirza
Hasan Mirza
MEMargaret H. Eng
Margaret H. Eng
Background: As the outbreak of coronavirus disease 2019 (COVID-19) has progressed, computed tomography has emerged as an integral part of the diagnosis alongside reverse transcriptase–polymerase chain reaction assays. Frequently encountered imaging findings include peripheral airspace consolidations; bilateral ground-glass opacities; and, less commonly, cavitation. Hilar lymphadenopathy is a rarely reported finding in the setting of COVID-19. Case presentation: A 73-year-old Caucasian woman presented to our hospital with fever and fatigue. She had a maximum body temperature of 102.3 °F with lymphopenia and thrombocytopenia. She was diagnosed with severe acute respiratory syndrome coronavirus 2 infection on the basis of a positive result from a reverse transcriptase–polymerase chain reaction of a nasopharyngeal swab sample. Contrast-enhanced chest computed tomography revealed multifocal, subpleural ground-glass opacities with nodular consolidations bilaterally. Computed tomography also demonstrated atypical bilateral hilar lymphadenopathy, a rarely reported imaging feature of COVID-19. Chest computed tomography 1 month before the presentation did not show focal consolidations or lymphadenopathy. This indicated that the findings were due to the patient’s severe acute respiratory syndrome coronavirus 2 infection. She received 5 days of oral hydroxychloroquine and experienced resolution of her symptoms. Conclusion: Chest computed tomography has been used extensively to diagnose and characterize the distinguishing radiological findings associated with viral pneumonia. It has emerged as an integral part of the diagnosis of COVID-19 alongside reverse transcriptase–polymerase chain reaction assays. Clinicians must be aware of uncommon clinical and radiological findings in order to diagnose this entity. Hilar lymphadenopathy is commonly seen with fungal infections, mycobacterial infections, and sarcoidosis. An extensive literature review found that bilateral hilar lymphadenopathy has not been reported in the setting of COVID-19. More data are needed to establish the clinical impact of this novel finding.

25 July 2020 in Respiratory Medicine Case Reports
Verified
Journal Article
Open access
MMMohsin Sheraz Mughal
Mohsin Sheraz Mughal
DDDenise Lauren V. Dalmacion
Denise Lauren V. Dalmacion
HMHasan Mahmood Mirza
Hasan Mahmood Mirza
IKIkwinder Preet Kaur
Ikwinder Preet Kaur
MCMaria Amanda Dela Cruz
Maria Amanda Dela Cruz
VKViolet E. Kramer
Violet E. Kramer
Inhalation of aerosolized products generated by different electronic devices is called vaping. E-cigarettes or Vaping product use Associated Lung Injury (EVALI) outbreak peaked in August–September 2019 and gradually declined. EVALI remains a diagnosis of exclusion which presents as an acute lung injury in the vaping population. Vitamin E acetate and its products are implicated as one of the cytotoxic agents causing airway centered pneumonitis. Lipid laden macrophages are found in samples of BAL fluid but their role in cytopathology of the disease remains unclear. We present a 57 years old man who came to the emergency department at Monmouth Medical Center, New Jersey in fall, 2019. Reportedly he has been vaping THC about 100g every day for past three days. At initial presentation, he had fever, shortness of breath and hypoxia requiring supplemental oxygen. He was empirically treated with levofloxacin 500 mg for five days without a significant improvement in his symptoms. Non-contrast chest CT scan showed bilateral ground-glass opacities, indicative of diffuse alveolar damage. He underwent flexible bronchoscopy to rule out infective pneumonia followed by auto-immune work-up that was non-conclusive. He was given 1 mg/kg methylprednisolone with a quick taper of oral steroids leading to the resolution of symptoms. At six months follow-up, imaging showed near resolution of ground-glass opacities.